These findings suggest that upregulated BCL11A gene expression in childhood ALLs may lead to MLL-r ALL development and BCL11A represents a new potential therapeutic target for childhood MLL-r ALL. This evidence concerns the gene BCL11A and acute lymphoblastic leukemia.